Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells

Cytokine

Volumn 59, Issue 2, 2012, Pages 228-236

  Wang, Yue ^a,b   Li, Lingzhi ^a,b   Guo, Xiaoqin ^a   Jin, Xin ^a   Sun, Weijia ^a   Zhang, Xiaolei ^a   Xu, Rui Cheng ^b  

^a MEDICAL COLLEGE OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

^b Tianjin Key Laboratory for Biomarkers of Occupational and Environmental Hazard   (China)

Author keywords

Interleukin 6; Interleukin 6 receptor; Ovarian cancer; Ras MEK ERK and PI3K Akt signaling; Tumorigenic properties

Indexed keywords

GELATINASE A; GELATINASE B; GLYCOPROTEIN GP 130; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B;

ANCHORAGE INDEPENDENT GROWTH; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CANCER CELL CULTURE; CANCER INVASION; CELL ADHESION; CELL CYCLE REGULATION; CELL PROLIFERATION; CYTOKINE PRODUCTION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

ANDROSTADIENES; APOPTOSIS; CELL ADHESION; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; FLAVONOIDS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; PHENOTYPE; PHOSPHORYLATION; PROTEOLYSIS; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION;

EID: 84862304990     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.04.020     Document Type: Article

References (46)

1. Risch H.A. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 1998, 90:1774-1786.
2. Agarwal R., Kaye S.B. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003, 3:502-516.
3. Trikha M., Corringham R., Klein B., Rossi J.F. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003, 9:4653-4665.
4. Mumm J.B., Oft M. Cytokine-based transformation of immune surveillance into tumor-promoting inflammation. Oncogene 2008, 27:5913-5919.
5. Twillie D.A., Eisenberger M.A., Carducci M.A., Hseih W.S., Kim W.Y., Simons J.W. Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 1995, 45:542-549.
6. Shariat S.F., Andrews B., Kattan M.W., Kim J., Wheeler T.M., Slawin K.M. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 2001, 58:1008-1015.
7. George D.J., Halabi S., Shepard T.F., Sanford B., Vogelzang N.J., Small E.J., et al. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. Clin Cancer Res 2005, 11:1815-1820.
8. Moradi M.M., Carson L.F., Weinberg B., Haney A.F., Twiggs L.B., Ramakrishnan S. Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer. Cancer 1993, 72:2433-2440.
9. Plante M., Rubin S.C., Wong G.Y., Federici M.G., Finstad C.L., Gastl G.A. Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer 1994, 73:1882-1888.
10. Scambia G., Testa U., Panici P.B., Martucci R., Foti E., Petrini M., et al. Interleukin-6 serum levels in patients with gynecological tumors. Int J Cancer 1994, 57:318-323.
11. Tempfer C., Zeisler H., Sliutz G., Haeusler G., Hanzal E., Kainz C. Serum evaluation of interleukin 6 in ovarian cancer patients. Gynecol Oncol 1997, 66:27-30.
12. Berek J.S., Chung C., Kaldi K., Watson J.M., Knox R.M., Martínez-Maza O. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol 1991, 164:1038-1042.
13. Scambia G., Testa U., Benedetti Panici P., Foti E., Martucci R., Gadducci A., et al. Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer 1995, 71:354-356.
14. Penson R.T., Kronish K., Duan Z., Feller A.J., Stark P., Cook S.E., et al. Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer 2000, 10:33-41.
15. Coward J., Kulbe H., Chakravarty P., Leader D., Vassileva V., Leinster D.A., et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res 2011, 17:6083-6096.
16. Syed V., Mlinski G., Mok S.C., Ho S.M. Reproductive hormone-induced, STAT3-mediated interleukin 6 action in normal and malignant human ovarian surface epithelial cells. J Natl Cancer Inst 2002, 94:617-629.
17. Wang Y., Yang J., Gao Y., Dong L.J., Liu S., Yao Z. Reciprocal regulation of 5alpha-dihydrotestosterone, interleukin-6 and interleukin-8 during proliferation of epithelial ovarian carcinoma. Cancer Biol Ther 2007, 6:864-871.
18. Yang J., Wang Y., Gao Y., Shao J., Zhang X.J., Yao Z. Reciprocal regulation of 17beta-estradiol, interleukin-6 and interleukin-8 during growth and progression of epithelial ovarian cancer. Cytokine 2009, 46:382-391.
19. Rabinovich A., Medina L., Piura B., Segal S., Huleihel M. Regulation of ovarian carcinoma SKOV-3 cell proliferation and secretion of MMPs by autocrine IL-6. Anticancer Res 2007, 27:267-272.
20. Nilsson M.B., Langley R.R., Fidler I.J. Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res 2005, 65:10794-10800.
21. Wang Y., Niu X.L., Qu Y., Wu J., Zhu Y.Q., Sun W.J., et al. Autocrine production of Interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett 2010, 295:110-123.
22. Li H.Z., Wang Y., Gao Y., Shao J., Zhao X.L., Deng W.M., et al. Effects of raf kinase inhibitor protein expression on metastasis and progression of human epithelial ovarian cancer. Mol Cancer Res 2008, 6:917-928.
23. Kleiner D.E., Stetler-Stevenson W.G. Quantitative zymography: detection of picogram quantities of gelatinases. Anal Biochem 1994, 218:325-329.
24. Alper O., DeSantis M.L., Stromberg K., Hacker N.F., Cho-Chung Y.S., Salomon D.S. Anti-sense suppression of epidermal growth factor receptor expression alters cellular proliferation, cell-adhesion and tumorigenicity in ovarian cancer cells. Int J Cancer 2000, 88:566-574.
25. Hirano T., Nakajima K., Hibi M. Signaling mechanisms through gp130: a model of the cytokine system. Cytokine Growth Factor Rev 1997, 8:241-252.
26. Watson J.M., Berek J.S., Martínez-Maza O. Growth inhibition of ovarian cancer cells induced by antisense IL-6 oligonucleotides. Gynecol Oncol 1993, 49:8-15.
27. Obata N.H., Tamakoshi K., Shibata K., Kikkawa F., Tomoda Y. Effects of interleukin-6 on in vitro cell attachment, migration and invasion of human ovarian carcinoma. Anticancer Res 1997, 17:337-342.
28. Kutteh W.H., Kutteh C.C. Quantitation of tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 in the effusions of ovarian epithelial neoplasms. Am J Obstet Gynecol 1992, 167:1864-1869.
29. Gastl G., Plante M., Finstad C.L., Wong G.Y., Federici M.G., Bander N.H., et al. High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer. Br J Haematol 1993, 83:433-441.
30. Schröder W., Ruppert C., Bender H.G. Concomitant measurements of interleukin-6 (IL-6) in serum and peritoneal fluid of patients with benign and malignant ovarian tumors. Eur J Obstet Gynecol Reprod Biol 1994, 56:43-46.
31. Chopra V., Dinh T.V., Hannigan E.V. Angiogenin, interleukins, and growth-factor levels in serum of patients with ovarian cancer: correlation with angiogenesis. Cancer J Sci Am 1996, 2:279-285.
32. Kryczek I., Gryboś M., Karabon L., Klimczak A., Lange A. IL-6 production in ovarian carcinoma is associated with histiotype and biological characteristics of the tumour and influences local immunity. Br J Cancer 2000, 82:621-628.
33. Bar J.K., Grelewski P., Popiela A., Noga L., Rabczynski J. Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors: correlation with Ki-67 and p53 immunoreactivity. Gynecol Oncol 2004, 95:23-31.
34. Bond M., Fabunmi R.P., Baker A.H., Newby A.C. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Lett 1998, 435:29-34.
35. Zhou H.Y., Pon Y.L., Wong A.S. Synergistic effects of epidermal growth factor and hepatocyte growth factor on human ovarian cancer cell invasion and migration: role of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase. Endocrinology 2007, 148:5195-5208.
36. Tamakoshi K., Kikkawa F., Nawa A., Ishikawa H., Mizuno K., Tamakoshi A., et al. Characterization of extracellular matrix-degrading proteinase and its inhibitor in gynecologic cancer tissues with clinically different metastatic form. Cancer 1995, 76:2565-2571.
37. Davidson B., Goldberg I., Gotlieb W.H., Kopolovic J., Ben-Baruch G., Nesland J.M., et al. The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma. Mol Cell Endocrinol 2002, 187:39-45.
38. Davies B., Brown P.D., East N., Crimmin M.J., Balkwill F.R. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 1993, 53:2087-2091.
39. Huang L.W., Garrett A.P., Bell D.A., Welch W.R., Berkowitz R.S., Mok S.C. Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors. Gynecol Oncol 2000, 77:369-376.
40. Liotta L.A., Stetler-Stevenson W.G. Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 1991, 51(Suppl. 18):5054s-5059s.
41. Kossakowska A.E., Edwards D.R., Prusinkiewicz C., Zhang M.C., Guo D., Urbanski S.J., et al. Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non-Hodgkin's lymphomas. Blood 1999, 94:2080-2089.
42. Steinmetz R., Wagoner H.A., Zeng P., Hammond J.R., Hannon T.S., Meyers J.L., et al. Mechanisms regulating the constitutive activation of the extracellular signal-regulated kinase (ERK) signaling pathway in ovarian cancer and the effect of ribonucleic acid interference for ERK1/2 on cancer cell proliferation. Mol Endocrinol 2004, 18:2570-2582.
43. Meng Q., Xia C., Fang J., Rojanasakul Y., Jiang B.H. Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway. Cell Signal 2006, 18:2262-2271.
44. Zhang J., Li Y., Shen B. PI3-K/Akt pathway contributes to IL-6-dependent growth of 7TD1 cells. Cancer Cell Int 2003, 3:1-4.
45. Lentzsch S., Chatterjee M., Gries M., Bommert K., Gollasch H., Dörken B., et al. PI3-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells. Leukemia 2004, 18:1883-1890.
46. Terakawa T., Miyake H., Furukawa J., Ettinger S.L., Gleave M.E., Fujisawa M. Enhanced sensitivity to androgen withdrawal due to overexpression of interleukin-6 in androgen-dependent human prostate cancer LNCaP cells. Br J Cancer 2009, 101:1731-1739.